🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06077305
Starting soon Observational

A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke

NCT06077305 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tiantan Hospital
Phase
Observational
Started
2023-10-30
Last updated
2023-10-19

Condition(s) studied

Cerebral Small Vessel DiseasesIschemic Stroke

Study summary

This study aims to construct a registry platform for microcirculatory disorders in a large sample of Chinese patients with cerebral small vessel disease and ischemic stroke; To explore the role of microcirculatory disorders in different types of cerebral small vessel disease and iachemic stroke, as well as their pathogenesis, severity, and prognosis; And to research on the drug treatment of microcirculatory disorders for cerebral small vessel disease and stroke in the real world.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: Study 1: 1. Age ≥ 18 years old. 2. Acute ischemic stroke within 7 days of onset. 3. Sign an informed consent form. Study 2: 1. Age ≥ 18 years old. 2. Ischemic stroke during recovery period, within 30 days to 1 year of onset. 3. Sign an informed consent form. Study 3: 1. Age ≥ 18 years old. 2. Within 3 years, there are characteristic lesions of cerebral small vessel disease on head MRI or CT, and they meet at least one of the following criteria: 1. Paraventricular or deep white matter hyperintensities, Fazekas total score ≥ 2; 2. Paraventricular or deep white matter hyperintensities, Fazekas total score=1, and at least two vascular risk factors (hypertension, hyperlipidemia, diabetes, current smoking, obesity, history of coronary heart disease, history of stroke). 3. Paraventricular or deep white matter hyperintensities, Fazekas total score=1, with ≥ 1 lacune. 4. New recent subcortical small infarcts. 3. Sign an informed consent form. Exclusion Criteria: Study 1: 1. Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset. 2. There are untreated cerebral vascular malformations or untreated aneurysms (diameter\>3mm). 3. Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc. 4. A mental illness diagnosed according to the DSM-V diagnostic criteria. 5. There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc. 6. Unable to cooperate in completing follow-up visits due to geographical or other reasons. 7. The patient also participated in other clinical trials. Study 2: 1. Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset. 2. There are untreated cerebral vascular malformations or untreated aneurysms (diameter\>3mm). 3. Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc. 4. A mental illness diagnosed according to the DSM-V diagnostic criteria. 5. There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc. 6. Unable to cooperate in completing follow-up visits due to geographical or other reasons. 7. The patient also participated in other clinical trials. Study 3: 1. Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset. 2. There are untreated cerebral vascular malformations or untreated aneurysms (diameter\>3mm). 3. Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc. 4. A mental illness diagnosed according to the DSM-V diagnostic criteria. 5. There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc. 6. Unable to cooperate in completing follow-up visits due to geographical or other reasons. 7. The patient also participated in other clinical trials.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Beijing China

More Beijing Tiantan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06077305 on ClinicalTrials.gov ↗ ← All trials in China